Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Predicting heart failure in asymptomatic diabetes: derivation and internal validation of a clinical prediction model for early detection of diabetic cardiomyopathy.

Frontiers in endocrinology·2026

Same author

Periodontal Disease-Like Manifestations in Patients Having Acute Leukemia With Normal Complete Blood Counts.

Case reports in dentistry·2026

Same author

Effect of GLP-1RA on blood eosinophil levels in adults: a real-world study.

BMC pulmonary medicine·2026

Same author

An interpretable nomogram for predicting early acute postoperative hypocalcemia in differentiated thyroid cancer: development and internal validation.

Frontiers in endocrinology·2026

Same author

A case report of a rare and distinctive pacing pattern during left bundle branch pacing in a child with third-degree atrioventricular block following ventricular septal defect repair.

Frontiers in cardiovascular medicine·2026

Same author

Extracellular Matrix-Related Prognostic Signature for Head and Neck Squamous Cell Carcinoma via Multi-Algorithm Survival Modeling.

Biomarker insights·2026

Search research articles

Related Experiment Video

Updated: Jul 7, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Targeting CD24 in Cancer Immunotherapy.

Wenwen Chen¹, Zhigang Hu¹, Zhigang Guo¹

¹Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, 1 Wenyuan Road, Nanjing 210023, China.

|December 23, 2023

Summary

Cluster of differentiation 24 (CD24) is a key cancer antigen. Therapies targeting CD24, including monoclonal antibodies and CAR T-cell therapy, are emerging as promising cancer treatments.

Keywords:

CD24 immunotherapy siglec-10

More Related Videos

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Experiment Videos

Last Updated: Jul 7, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Area of Science:

Oncology
Immunology
Molecular Biology

Background:

Immunotherapy is a critical cancer treatment modality.
Identifying tumor antigens is key for effective cancer immunotherapy.
Cluster of differentiation 24 (CD24) is a highly expressed tumor-associated antigen across various cancers.

Purpose of the Study:

To review current and future therapeutic strategies targeting CD24.
To highlight CD24's role as a tumor antigen in cancer progression.

Main Methods:

Literature review of studies on CD24 as a cancer target.
Summary of existing therapeutic approaches including monoclonal antibodies, antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapy, and CAR-NK cell therapy.
Analysis of CD24's involvement in cancer-related signaling pathways and immune interactions.

Main Results:

CD24 is frequently overexpressed in diverse tumor types.
CD24 influences tumor progression through interactions with signaling pathways and immune cells.
Multiple therapeutic modalities targeting CD24 are under investigation and development.

Conclusions:

CD24 represents a promising target for novel cancer immunotherapies.
Further research into CD24-targeted therapies could lead to improved cancer treatment outcomes.
Combination strategies involving CD24-targeting agents may enhance therapeutic efficacy.